B and T cells are not required for the viable motheaten phenotype by unknown
B  and T  Cells Are Not Required for the 
viable motheaten Phenotype 
By Calvin C. K.Yu,*~ Hing-Wo Tsui,*ll BoY. Ngan, r 
Marc J. Shulman,* Gillian E.Wu,*g and Florence W. L.Tsui*ll 
From the Departments of*Immunology  and $  Pathology, University of  Toronto, Toronto M 5 S  1A8; 
the ~  Wellesley Hospital Research Institute, Toronto M4Y 1J3; and the IIToronto Hospital Research 
Institutes, Toronto, Ontario, Canada M5T 2S8 
Summary 
Hematopoietic cell phosphatase (HCP), encoded by the hcph gene, (also called PTPIC, SHP, 
SH-PTP1, and PTPN6) is deficient in motheaten  (me~me), and the allelic  viable motheaten (meV/ 
me  ~) mice. Since HCP is expressed in many cell types and protein phosphorylation is a major 
mechanism of regulating protein function, it is not surprising that the motheaten phenotype is 
pleiotropic. It is commonly thought that immune system involvement causes this disease.  If so, 
the motheaten disease ought to be alleviated when the recombination activation gene-1 (RAG-1) 
is disrupted because there will be no V(D)J rearrangement and thus impaired development of  B 
and T cells. We bred homozygous, double-mutant meV/meV'RAG - 1 -/- mice and found that, in 
fact, they developed full-blown motheaten inflammatory disease,  including pneumonitis, alope- 
cia,  inflamed paws,  and splenomegaly with elevated myelopoiesis. Thus, except for autoanti- 
bodies, the motheaten phenotype does not depend on the presence of B and T  cells. This obser- 
vation cautions the use of motheaten mice as a model of autoimmune disease. 
p rotein tyrosine kinases  and phosphatases play a major 
role in protein tyrosine phosphorylation, a process that 
regulates cell growth and proliferation. Some understand- 
ing of the physiological role of particular protein kinases 
and phosphatases  can be  inferred from the  phenotype of 
mutant  animals.  In  the  case  of hematopoietic  cell phos- 
phatase (HCP) l  (1-5), which is deficient in mice homozy- 
gous for the motheaten (me~me) mutations (6--8), the mutant 
phenotypes have been intensively studied. The me~me mice 
and the allelic  me"/me  ~ mice are severely immunodeficient. 
In both  motheaten  mutants,  maturations  of B  and T  lym- 
phocytes  are  impaired.  Both  me~me  and  viable  motheaten 
(me~/mr ') mice also develop the so-called autoimmune dis- 
eases characterized by patchy alopecia (hence the name) (9, 
10),  inflamed  paws  (11),  and  hypergammaglobulinemia 
(12).  Typically, their serum has high titers of autoreactive 
antibodies  (9-13),  and immune  complexes are present in 
various tissues, such as the skin, lung, and kidney (10). The 
mutant  animals  died prematurely,  usually of pneumonitis 
characterized by the  accumulation  of macrophages,  lym- 
phocytes, and granulocytes in the lungs (10,  14). 
Since systemic autoimmune diseases  usually result from 
complex interactions among lymphoid (B and T) cells and 
target tissues, it is difficult to distinguish the contribution of 
1Abbreviations used in this  paper: HCP, hematopoietic  cell phosphatase; me/ 
me, motheaten mice; me~/me  ~, viable motheaten mice; RAG-l, recombina- 
tion activation  gene-1; SSCP, single-strand conformation  polymorphism. 
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each cell type in the initiation of the autoimmune response 
and the induction of specific pathological lesions.  The pres- 
ence of lymphocytes and  complexes in affected tissues  in 
both motheaten mutants has suggested that the immune sys- 
tem might contribute importantly to the motheaten pheno- 
type. This hypothesis predicts that the motheaten phenotype 
will be alleviated by disruption in the recombination acti- 
vation  gene-1  (RAG-l),  a  null  mutation  that  prevents 
V(D)J  rearrangement  and  thus  prevents  development  of 
antigen specific B and T  cells (15).  To test this prediction, 
we  generated  and  studied  double-mutant  mice,  meV/me  v 
RA G- 1  -/-. The me  v/me  v RA G- 1 -/-  mutant mice develop 
disease  characteristic of the motheaten phenotype, including 
pneumonitis, inflammation of the skin and extremities, and 
splenomegaly with elevated myelopoiesis. Thus, except for 
autoantibodies,  all  manifestations  of the  motheaten  disease 
occur in the absence orB and T  cells. 
Materials and Methods 
Mice.  The founding  C57BL/6J  +/me  ~ mice were obtained 
from The Jackson Laboratory (Bar Harbor, ME), and the found- 
ing  RAG-1 -/-  mice  were  kindly  provided by  S.  Tonegawa 
(Massachusetts Institute of Technology, Cambridge,  MA). Mice 
were maintained at the animal facility of the Ontario Cancer In- 
stitute  (Toronto), and kept in microisolator housing units  (Lab 
Products,  Maywood,  NJ)  in  rooms  equipped  with  the  Hepa- 
filtered air handling system. Cages, bedding, and water were ster- 
ilized by autoclaving, and  food was  sterilized by ",/-irradiation. 
Mice were handled by aseptic forceps or aseptic gloves. 
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Figure  1.  Generation of mice  with  various  geno- 
types  at the mS' and RAG-1  loci.  Since me'~me "  mice 
are  sterile,  mice  heterozygous  at  the  me"  locus  were 
used for breeding. The founding +/me  v and RAG- 1-/- 
parents were from the C57BL/6J and 129/Sv ￿  CD1 
backgrounds,  respectively.  The  F1  +/meV'RAG-I  +/ 
mice  were  back-crossed to  the  RAG-I  -/-  parent to 
generate the F2 generation. The F2 mice were then in- 
tercrossed  to generate the F3  generation, which were 
obtained by the following crosses: (I) cross among the 
+/meV'RAG-I  +/  mice,  (2)  cross  among  the  +/ 
me~'RAG-1  -/  mice,  and  (3)  cross  between  the  +/ 
mev'RAG-1  +/-  mice and +/meV'RAG-1  -/-  mice.  The 
F3  generation consisted  of mice of all possible  geno- 
types, i.e., the normal control mice (i.e., mice that have 
at  least  one  wild-type  allele  at  each  of the  me  v  and 
RAG-1  loci),  the RAG-1  i  control mice (i.e.,  mice 
that are homozygous for the RAG-1 null mutation and 
have at least one wild-type allele at the me  ~ locus), the 
me"/me ~ control mice (i.e.,  mice that are  homozygous 
for the me" mutation and have at least one wild-type al- 
lele at the RAG- I locus), and the double-mutant mice 
(i.e., mice that are homozygous for both the me  ~ muta- 
tion and RAG- 1 null mutation). 
Genetic  Testing.  The  strategy  used  for  typing  the  me v  locus 
was to amplify the region of the genome containing the me" mu- 
tation by PCR  and then  to  examine  the  amplified  products by 
single-strand conformation  polymorphism  (SSCP)  analysis.  The 
primers used for amplifying a  167-bp fragment in which the  me v 
mutation is located were 5'-TGTCATCGTCATGACTACC-3' 
and 5'-TCAGGCTTGGCAGCAAACTCG-3'.  The latter primer 
was  kinased with  [33p]ATP.  PCR  conditions used were  15  s  at 
94~  15 s at 54~  and 15 s at 72~  for 30 cycles. The amplified 
products  were  then  subject  to  SSCP  analysis:  a  portion  of the 
PCR product was boiled for 3 rain, quickly chilled on ice, loaded 
on an MDE (J.T. Baker Chemical Co., Phillipsburg, NJ) gel, and 
run at 3 W  for 19 h. The gel was dried, and the DNA was visual- 
ized by autoradiography. 
The RAG-1  locus was typed by PCR  of the region of the ge- 
home containing the disruption in RAG-1.  The primers used for 
amplifying an 809-bp RAG- I fragment present only in the wild-type 
allele were 5'-ATCTCCTGCCAGATATGCGAA-3'  and 5'-AAC- 
CTCTTCGAATGGTATCT-3'.  The primers used for amplifying 
a 477-bp  neo  fragment present only in the RAG-1  disrupted allele 
were  5'-ATGATTGAACAAGATGGATTGC-3'  and 5'-TCC- 
AGATCATCCTGATCGAC-3'.  The PCR  conditions used were 
15 s at 94~  15 s at 61~  and 30 s at 72~  The extension time was 
increased by 3  s per  cycle  for a  total of 30  cycles.  The  amplified 
DNA was subjected to agarose gel electrophoresis and then visual- 
ized by fluorescence of ethidium bromide under ultraviolet light. 
Flow  Cytometry.  Cells taken fi'om 5-wk-old mice were  stained 
with FITC-conjugated anti-IgM heavy chain  (33.60)  (16),  FITC- 
conjugated anti-CD4 (RM4-5; PharMingen, San Diego, CA), PE- 
conjugated anti-CD8oL (53-6.7; PharMingen), and PE-conjugated 
anti-Mac-1  (MI/70; Biosource International, Camarillo, CA) an- 
tibodies separately. Briefly, 2  X  10  s cells were incubated with the 
appropriate  antibodies  (1  I~g/106  cells)  in  100  ILl  PBS  plus  5% 
FCS  (GIBCO BRL,  Gaithersburg, MD)  for 20 min on ice.  The 
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Figure  2.  (a) Genetic typing identified mutant mice with different genotypes by the distinct DNA patterns. (b) Flow cytometry analysis indicates that 
the B and T  cell-specific surface markers IX, and CD4, CD8~x,  respectively, are not detectable on the spleen cells obtained from the double-mutant and 
RAG- 1  -/  control. Analysis was carried out on live cells, i.e., the cells included by the 1<1 gate on the forward scatter (FSC) vs. side scatter (SSC) profile. 
3-6-wk-old mice were analyzed. 
stained cells were  then washed with PBS plus 5% FCS, and were 
analyzed by flow cytometry. 
Histological Analysis.  Tissues were taken from mice of various 
ages (from 1 to 15 wk).  Cross-sections of 4-8-1*m thick were oh- 
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tained from wax-embedded  tissue samples and stained with  he- 
matoxylin and eosin.  Representative sections of the different tis- 
sues are shown in Figs. 5 and 6. 
Statistical  Analysis.  The  statistical  significance  of  differences Table 1.  Characteristics  of the motheaten  and RAG-1  Mutants* 
Motheaten  +/"  Motheaten  +/"  Motheaten  ~/~  Motheaten  v/~ 
RAG-1  +/"  RAG-1  /-  RAG-I  +/"  RAG-1  -/ 
Median life span* (d)  >275 (n =  49)  190 (n =  80)  72 (n =  16)  97 (n =  31) 
Skin: focal alopecia~  0/48  0/79  8/13  9/23 
Extremities: swelling and lesionsll  0/48  0/79  11/13  19/29 
Lung abnormalities￿82  4 / 9  8 / 12  5 / 7  12 / 12 
Inflammation**  4/9  8/12  3/7  11/12 
In  traalveolar erythrocytes  1/9  2/12  3/7  5/l 2 
Mqb with crystalline materiaF~:  0/9  0/12  0/7  8/12 
Spleen: splenomegaly~  1/8  I / 10  7/7  7/10 
* +/. denotes at least one wild-type allele; v denotes the allele carrying the viable motheaten mutation. 
$Survival analyses indicate that the double-mutant  and the meVme" control do not differ significantly in the probability of survival at any given time 
(see Fig. 3). 
~Difference between the mev/me v control and double-mutant is not significant (P =  0.299 in Fisher's exact test). 
IIDifference  between the mev/me  ~' control and double-mutant is significant (P =  0.047 in Fisher's exact test). 
￿82  scored abnormally if they contained one or more of the three pathological characteristics, i.e., inflammation, intraalveolar erythrocytes, and 
M~ with crystalline material. 
**Difference between the meVme  ~ control and double-mutant  is significant (P =  0.038 in Fisher's exact test). 
**Difference between the me'~me  ~ control and double-mutant is significant (P =  0.006 in Fisher's exact test). 
55Splenomegaly  was scored by visual inspection. 
between sample means was based on Cox regression analysis (for 
survival analysis), chi square (X  2) test (for genotype analysis), and 
Fisher's exact test (for all other analyses).  In all tests,  differences 
are treated as significant when P <0.05. 
Results 
Generation  and Analysis of  Mutant Mice.  The breeding scheme 
and designation of the various control mice are described in 
Fig. 1. We analyzed 30 informative litters. The genotype of 
each  mouse  was  determined  by  DNA  PCR  and  SSCP 
analysis for the me  v locus and by PCR for the RAG-1 locus 
(Fig. 2 a). When mice were killed, the genotypes were ver- 
ified by flow  cytometry,  analyzing spleen  cells with  anti- 
bodies recognizing the IgM heavy chain (be), CD4,  CD8ci, 
and Mac-1  (Figs. 2  b and 6 e). Litter sizes ranged from  1 to 
12,  and the frequencies of the various genotypes were  not 
significantly  different  from  the  expected  Mendelian  fre- 
quencies, i.e., 0.150  of the mice were me'~me  ~ control (ex- 
pected frequency  --  0.149,  n  =  107,  X  2 P  >0.900),  and 
0.194 of the mice were double mutant (expected frequency = 
0.155,  n  =  160,  X  2 P  >0.250).  The  expected frequencies 
are calculated by taking into account of the various types of 
crossing that  were  carried  out  to  generate  a  given  geno- 
type.  For  example,  double-mutant  mice  were  obtained 
from  three  types  of  crossing  (see  Fig.  1),  i.e.,  (1)  +/ 
me~.RAG-1 +/+  5<  +/me~.RAG-1  +/-,  with  a  P  =  0.0625 
for generating the double mutant;  (2)  +/me~'RAG-1  -/  ￿ 
+/meV'RAG-I  -/-,  with  a  P  =  0.25  for  generating  the 
double mutant; and (3)  +/me v"  RAG-1  +/-  ￿  + /meV'RAG- 
1 -/-,  with P  =  0.125  for generating the double mutant. A 
total of 35  mice were  generated from the type  1 crossing, 
56  mice  from  the  type 2  crossing,  and  69  mice from  the 
type 3  crossing. The expected frequency of generating the 
double mutant is therefore  [(35)(0.0625) + (56)(0.25) + (69) 
(0.125)]/160=0.155.  There  was  no  significant difference 
between the observed and expected frequencies of the var- 
ious  mutant  mice  carrying  the  meV/me  v  genotype.  Thus, 
there seems to be little selection against the meV/me  v mice in 
utero whether or not RAG-I is expressed. 
Effect on Life Span.  Each  mouse  was  also  examined for 
characteristics normally present in mice defective in HCP: 
shortened life span,  dermatitis, inflammatory lesions in the 
extremities, hemorrhagic pneumonitis, and extramedullary 
myelopoiesis sites. The median hfe span of the double mu- 
tants (97 d) was similar to that of the meV/me  ~ control (72 d) 
but substantially shorter than that of the RAG-1  -/  control 
(190  d)  and  normal control  (>275  d)  (Table  1).  By using 
the proportional hazard model and Cox regression analysis 
(Fig. 3 and reference 17), which take into account the mice 
that were alive, killed, and dead at the end of the study, we 
are able to conclude that the absence of RAG-1 expression 
does  not  significantly affect  the  probability of survival of 
the meg'~me v mice at any given time. 
Dermatitis in me"/meV'RAG-1  /- Mice.  Severe  dermati- 
tis  with  patchy  alopecia  is  the  hallmark  of the  motheaten 
phenotype  (9,  10).  Both  the  meV/me  ~ control and double- 
mutant mice in our study manifested the disease with ruf- 
fled,  "spotty" fur,  indicating irregular hair growth  (Fig.  4 
a-d). 9 out of 23 double-mutant mice and 8 out of 13 meV/ 
me  v control mice had these skin lesions (Table 1).  Since the 
frequency of skin lesions in the double mutant is not signif- 
icantly different from that in the  me"/me  ~ control, the skin 
lesions in the me"/me  v mice are not caused by B  or T  cells. 
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Figure 3.  Survival curve of mice with the various genotypes. The proportional hazard model using the Cox regression analysis indicates that, at any 
given time, the probability of survival of  the double-mutant is not significantly different from that of  the md'/me  ~ control (P >0.540). However, the prob- 
ability of  survival of the double mutant is significantly lower than that of the RAG-1  -/-  control (P <0.001) and the normal control (P <0.001). There is 
weak evidence of a difference in the probability of survival between the RAG-1  -/-  control and the normal control (P >0.070). 
Inflammatory Lesions in the Extremities.  Both the meV/me  ~ 
control and double-mutant mice developed the characteris- 
tic inflammation in the paws:  extensive swelling and open 
pustular  lesions.  The  paw  lesions  typically appeared  be- 
tween 5 and 10 d after birth, and the severity of these swell- 
ings and lesions was of the same magnitude (Fig. 4, e-g). The 
frequencies of paw deformities in the  meV/me  v control (11 
of 13)  and  double-mutant  mice  (19  of 29)  were  similar 
(Table  1). The reason for incomplete penetrance of these 
symptoms is unknown, but may be caused by a variation in 
the time of onset of the disease. 
Lung Abnormalities.  Lung abnormalities characteristic of 
pneumonitis were present in N70% of the meV/me  ~ control 
and in all double-mutant mice examined (Table 1). These 
pneumonitis-like  characteristics  were  the  likely  cause  of 
death of these mice during the first few months of life (Ta- 
ble  1 and Fig.  3).  Histological analysis  revealed severe in- 
flammation in the lungs of both me~/me  v control and dou- 
ble-mutant mice (Table 1 and Fig.  5 c-e). A proportion of 
the normal control and RAG-I  -/-  control mice had some 
inflammation  (Table  1),  but  it was  a  much  milder  form 
than that in the lungs of the meP/me  v control and double- 
mutant mice (Fig. 5, a and b). A large amount of crystalline 
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material, which appears to be associated with degradation 
of erythrocytes (10),  is present inside  the  alveolar macro- 
phages  of the  double-mutant mice.  This  abnormality has 
also been observed by Shultz (10), who reported crystalline 
material  in  macrophages in  the  C57BL/6J  meV/me  v  mice. 
The reason for their absence in the meV/me  ~ control in the 
present study is unknown. Since the meV/me  v control mice 
in our study are of a mixed genetic background (see Fig.  1), 
however, strain-specific factors may modulate the severity 
of the lung abnormalities. No crystalline material was de- 
tected in  the  lung  sections  of the  RAG-1  -/-  control  or 
normal control (Table 1). These results lead to the conclu- 
sion that in the absence of B and T  cells,  meV/me  v mice de- 
velop severe hemorrhagic pneumonitis. 
ExtramedullaryMyelopoiesis.  Elevated  myelopoiesis  in 
the  spleen of the  C57BL/6  meV/me  v  mice  results  in  sple- 
nomegaly (10).  In the present study, the incidence of sple- 
nomegaly was  similar in the  me"/me  v control and double- 
mutant mice (Table 1). The spleens of these mice generally 
had  no  organized white pulp  (Fig.  6  a-d)  and  contained 
more than fivefold higher numbers of myeloid cells, as de- 
tected by anti-Mac-1  antibody,  than  the  normal  control 
and RAG-1  -/-  control mice (Fig. 6 e). Figure  4.  Double-mutant  and 
me'~me  v  control mice have similar 
gross phenotypes. Inflammation in 
the skin is evident from the "spotty" 
fur:  (a)  C57BL/6J  +~me  v  mouse 
(left) has smooth, shiny fur, whereas 
the  congenic C57BL/6J  meV/me  ~ 
mouse (right)  has  ruffled fur inter- 
spersed  with  patchy alopecia;  (b) 
RAG-I  -/-  control has  normal- 
looking fur; (c)  me'~me  " control and 
(d) double-mutant mice have ruffled 
fur with "spots," indicating  irregular 
hair growth. Normal paws are found 
in  (e)  RAG-1  -I-  control mice, 
whereas swollen paws with lesions 
were found in (~  me~/me  ~  control 
and (g) double-mutant mice. 
Discussion 
Since  the  RAG-I  mutation used  in  the  present  study 
completely and  specifically blocks  the  development of B 
and T  cells, our results indicate that except for the produc- 
tion of autoantibodies, the manifestations of the  motheaten 
inflammatory disease occur in the absence of the antigen- 
specific arm of the immune system. Contrary to our find- 
ings, Shultz and Sidman (18) reported that the me"/me  v scid/ 
scid  mice had a threefold increase in life span as compared 
to the  me"/me  v  mice. This difference in life span might be 
because the effects of the scid mutation are not limited to B 
and T  cells (19, 20). Moreover, earlier studies using mouse 
mutations that partially block either B  or T  lymphopoiesis 
are  consistent with our analysis of the  completely B-  and 
T-deficient meV/meV'RAG-1  -/-  mutant mice.  Scribner et 
al.  (21)  and Shultz (14)  observed that neither the presence 
of  the  xid  mutation,  which  impairs  the  production  of 
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mutant mice  reveals severe  inflammation.  The  lungs  of (a) 
normal control and (b) RAG-1 -/-  control mice are relatively 
normal.  (c) The lungs of me'~me  ~ control mice typically have 
inflammation characterized by interstitial fibrosis, resulting in 
greatly reduced air space. (d) The lungs of double-mutant  mice 
typically have inflammation characterized by a large number of 
alveolar macrophages containing crystalline material and infil- 
tration ofgranulocytes.  (e) The presence ofintraalveolar eryth- 
rocytes are also common in the double-mutant mice. Histo- 
logical sections were obtained from 3-6-wk-old mice. ￿ 
CD5 + B  cells, nor the presence of the nude mutation, which 
blocks T  cell development, prevented the manifestations of 
the  motheaten  phenotype,  respectively.  These  studies,  al- 
though  informative,  did  not  generate  a  definitive conclu- 
sion about the role of B  and T  cells in the motheaten disease, 
since  neither  the  xid  nor  the  nude  mutation  ablates  both 
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functional B  and  T  cells  (22-25).  However,  our  analysis 
taken together  with  these  previous studies  argues  that  the 
motheaten phenotype does not require B  and T  cells. Alto- 
gether,  these observations call into question the use of me~ 
me and me~/me  v mice as a paradigm ofautoimmune  disease. 
The  exact cell lineages responsible for the motheaten dis- Figure 6.  Extramedullary myelopoiesis of  the me~/me  ~ control and the double-mutant  mice. (a) The white pulps in the spleen of the normal control are 
well structured. No organized white pulp is observed in the (b) RAG-I  -/-  control,  (c) me~/me  v control, or (d) double-mutant mice. (e) Large absolute 
numbers of cells stained positive for Mac-1 are present in the me~/me  ~ control and double-mutant  mice. In comparison, the spleens of the nom~al control 
and RAG-1  /  control have low absolute numbers of the Mac-1 + cells, although the frequency of these cells is high in the RAG-1 -/-  control because of 
the absence of B and T cells. Analysis was carried out on live cells (see Fig. 2 b). The error bars of the histograms are SE values from two experiments. 
Spleens were obtained from 3-6-wk-old mice for analysis. 
ease  are  not known.  Infiltration of the  affected mouse  or- 
gans by monocytes, macrophages,  and granulocytes suggest 
that these  cell types are the primary effectors  of inflamma- 
tion in the  meV/me v mice.  Consistent with this notion is the 
observation that treatment with an antibody against CD1 lb, 
a subunit of Mac-1  whose expression is restricted to mono- 
nuclear phagocytes, granulocytes, and NK cells (26, 27) in- 
hibits  inflammation  in  me v  bone  marrow  chimeric  mice 
(11).  Since the  NK  cells of me  v  mice have virtually no ac- 
tivity and are present at only 30-50%  of the normal levels 
(28),  the  CD11b  study  suggests  that  myeloid  cells  are  re- 
sponsible for the inflammatory disease of the me~me  mice (11). 
Cells of nonhematopoietic origin may also contribute to 
the motheaten  diseases. Although HCP is expressed predom- 
inantly in bone  marrow,  thymus,  and  hematopoietic  cell 
lines (3, 4, 29), it is detected in low abundance in a few ep- 
ithelial cell lines and nonhematopoietic cancer cell lines (4, 
29).  Mutating HCP  in a  cell-specific manner should delin- 
eate the cell types that are important in the manifestation of 
the motheaten  disease. 
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